The CSL Ltd (ASX: CSL) share price has fallen 12% in 2 weeks now. This is significant considering the size of the company. We take a look!
The post CSL (ASX:CSL) share price is now down 12% in 2 weeks appeared first on The Motley Fool Australia. –
The CSL Ltd (ASX: CSL) share price seems to be stuck in the doldrums over the last couple of weeks. Shares in the biotherapeutics giant have been on the decline since the company announced its half-year results 2 weeks ago.
Interestingly, CSL reported a significant 45% increase in its net profit after tax. So why is the share price falling? As always, the devil is in the details.
Dividends cut in Aussie dollar terms
No, it’s not CSL picking favourites between the United States and Australia. Due to CSL’s operations being heavily focused in the US, most of the company’s financials are shown in US dollar terms. This causes fluctuations when interchanging between multiple currencies.
In this case, CSL declared a dividend increase of 9% to US$1.09 per share. However, the Australian dollar has strengthened by 17% compared to the USD in the last year. That means the Australian equivalent is actually less. In fact, CSL would have had to increase its dividend by more than 17% for it to increase on last year’s payout for Aussies.
Yesterday’s GDP figures indicate that the currency issue could worsen. Australia’s economy is rebounding strongly, backed up by the surprising 3.1% of GDP growth for the last quarter. The CSL share price also tumbled 1% yesterday.
The disappointing dividend for Australian shareholders is likely in focus today as CSL’s shares go ex-dividend. Meaning, if shareholders wanted to collect this dividend, but don’t want to stick around for the next one, today is the last day they had to wait around for.
CSL COVID-19 vaccine is a straggler
While Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) were provisionally approved earlier in the year, the AstraZeneca (LON: AZN) COVID-19 vaccine that CSL is set to manufacturer locally took a bit longer.
Furthermore, as reported by The Australian Financial Review, the AstraZeneca vaccine has lower efficacy than the Pfizer vaccine.
CSL resorted to an agreement for producing the AstraZeneca vaccine. This came after the company abandoned its own development attempts with the University of Queensland. This decision was made after participants gave false positive readings for HIV.
Foggy future weighs on CSL’s share price
Management warned that plasma collections had been impacted due to the challenging environment in its half results. As a result, CSL had experienced additional costs associated with collecting plasma.
Additionally, analysts at Goldman Sachs made the decision to downgrade CSL’s rating to a neutral. Analysts were concerned that management only reaffirmed guidance on the strong profit lift, instead of upgrading. This was interpreted by the analysts as potentially signalling headwinds for the company.
Accounting for today’s move, the CSL share price has now fallen by 16.5% in the last 12 months.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why are these ASX 200 healthcare shares sinking today?
- 2 fantastic blue chip ASX 200 shares to buy
- 5 things to watch on the ASX 200 on Thursday
- Is it time to buy these 2 hot ASX healthcare shares?
- What you need to know about the CSL (ASX:CSL) dividend
Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.